233 related articles for article (PubMed ID: 34589387)
1. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression.
Li X; Gohain N; Chen S; Li Y; Zhao X; Li B; Tolbert WD; He W; Pazgier M; Hu H; Lu W
Acta Pharm Sin B; 2021 Sep; 11(9):2655-2669. PubMed ID: 34589387
[TBL] [Abstract][Full Text] [Related]
2. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
4. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
Liu M; Li C; Pazgier M; Li C; Mao Y; Lv Y; Gu B; Wei G; Yuan W; Zhan C; Lu WY; Lu W
Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14321-6. PubMed ID: 20660730
[TBL] [Abstract][Full Text] [Related]
5. Calculation of hot spots for protein-protein interaction in p53/PMI-MDM2/MDMX complexes.
Huang D; Qi Y; Song J; Zhang JZH
J Comput Chem; 2019 Apr; 40(9):1045-1056. PubMed ID: 30549062
[TBL] [Abstract][Full Text] [Related]
6. Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy.
Niu F; Yan J; Ma B; Li S; Shao Y; He P; Zhang W; He W; Ma PX; Lu W
Biomaterials; 2018 Jun; 167():132-142. PubMed ID: 29571049
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of how stress-induced MDMX phosphorylation activates p53.
Chen X; Gohain N; Zhan C; Lu WY; Pazgier M; Lu W
Oncogene; 2016 Apr; 35(15):1919-25. PubMed ID: 26148237
[TBL] [Abstract][Full Text] [Related]
8. Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics.
He W; Yan J; Li Y; Yan S; Wang S; Hou P; Lu W
J Control Release; 2020 Sep; 325():293-303. PubMed ID: 32653500
[TBL] [Abstract][Full Text] [Related]
9. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
[TBL] [Abstract][Full Text] [Related]
10. d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions.
Li X; Liu C; Chen S; Hu H; Su J; Zou Y
Bioorg Med Chem Lett; 2017 Oct; 27(20):4678-4681. PubMed ID: 28916339
[TBL] [Abstract][Full Text] [Related]
11. An ultrahigh affinity d-peptide antagonist Of MDM2.
Zhan C; Zhao L; Wei X; Wu X; Chen X; Yuan W; Lu WY; Pazgier M; Lu W
J Med Chem; 2012 Jul; 55(13):6237-41. PubMed ID: 22694121
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
Phan J; Li Z; Kasprzak A; Li B; Sebti S; Guida W; Schönbrunn E; Chen J
J Biol Chem; 2010 Jan; 285(3):2174-83. PubMed ID: 19910468
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for inhibition of the MDM2:p53 interaction by an optimized MDM2-binding peptide selected with mRNA display.
Nagata T; Shirakawa K; Kobayashi N; Shiheido H; Tabata N; Sakuma-Yonemura Y; Horisawa K; Katahira M; Doi N; Yanagawa H
PLoS One; 2014; 9(10):e109163. PubMed ID: 25275651
[TBL] [Abstract][Full Text] [Related]
14. Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression.
Chen S; Li X; Li Y; Yuan X; Geng C; Gao S; Li J; Ma B; Wang Z; Lu W; Hu HG
Theranostics; 2022; 12(15):6665-6681. PubMed ID: 36185610
[No Abstract] [Full Text] [Related]
15. Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors.
Cheng X; Chen R; Zhou T; Zhang B; Li Z; Gao M; Huang Y; Liu H; Su Z
Nat Commun; 2022 Feb; 13(1):1087. PubMed ID: 35228542
[TBL] [Abstract][Full Text] [Related]
16. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
17. Functional Interrogation of the N-Terminal Lid of MDMX in p53 Binding via Native Chemical Ligation.
Chen X; Lu W
Chem Pharm Bull (Tokyo); 2016; 64(7):1004-8. PubMed ID: 27373663
[TBL] [Abstract][Full Text] [Related]
18. A tetrameric protein scaffold as a nano-carrier of antitumor peptides for cancer therapy.
Ma B; Niu F; Qu X; He W; Feng C; Wang S; Ouyang Z; Yan J; Wen Y; Xu D; Shao Y; Ma PX; Lu W
Biomaterials; 2019 Jun; 204():1-12. PubMed ID: 30861422
[TBL] [Abstract][Full Text] [Related]
19. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
20. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
